GSK Bio
NEWS
The Lynparza approval isn’t as broad as the Zejula approval, with Lynparza not approved for use in patients with homologous recombination deficiencies.
Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Life sciences and pharma companies strengthen their leadership teams and board with this week’s Movers & Shakers.
Zejula, GlaxoSmithKline’s once-daily PARP inhibitor, won regulatory approval as a monotherapy maintenance treatment for women with advanced ovarian cancer whose disease is responsive to first-line platinum-based chemotherapy, regardless of biomarker status.
Italian ReiThera Srl., German LEUKOCARE AG, and Belgian Univercells S.A., announced a strategic collaboration for the development and large-scale manufacturing of a novel adenoviral vector-based vaccine against COVID-19.
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.
The discovery that immune T cells have a spectrum of responsiveness could shed light on how our immune system responds to infections and cancer, and what goes wrong in immune diseases.
Pharma and life sciences companies boost their executive ranks and boards with this week’s Movers & Shakers.
The two companies will evaluate a smartphone-based self-testing solution for COVID-19, using Luminostics’ innovative technology and Sanofi’s clinical research abilities.
JOBS
IN THE PRESS